LY2784544
(Synonyms: Gandotinib) 目录号 : GC13848
Potent inhibitor of JAK2
Cas No.:1229236-86-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
Ba/F3 cells expressing JAK2V617F are placed in RPMI-1640-containing vehicle (DMSO) or Gandotinib (LY2784544) (concentration range, 0.001-20 μM) (1×104 cells/96-well). Ba/F3 cells expressing wild-type JAK2 are treated similarly except IL-3 (2 ng/mL) is added. After a 72-hour incubation, cell proliferation is assessed by adding Cell Titer 96 Aqueous One Solution Reagent (20 μL/well). The IC50 for inhibition of cell proliferation is calculated using the GraphPad Prism 4 software[1]. |
|
Animal experiment: |
Mice[1]Dose- and time-dependent in vivo inhibition of JAK2V617F signaling is assessed by measuring inhibition of STAT5 phosphorylation in a mouse ascitic tumor model. Ba/F3-JAK2V617F-GFP cells (1×107) are implanted in the intraperitoneal cavity of severe combined immunodeficiency mice (SCID mice) and allowed to develop into ascitic tumors for 7 days. For dose-response studies (six animals/group), Gandotinib (LY2784544) is administered once by oral gavage (2.5, 5, 10, 20, 40, or 80 mg/kg), then 30 min later, ascitic tumor cells are collected, fixed, incubated for 2 h with Mouse-anti-pSTAT5 (pY694) Alexa Fluor 647 (1:10 dilution), and analyzed by flow cytometry. Time course studies are performed similarly, except the animals are treated with Gandotinib (LY2784544) at 20, 40 or 80 mg/kg and ascitic tumor cells collected at prespecified intervals of 0.25-6 h after dosing. Data are analyzed by the one-way analysis of variance, and Dunnett's test (α=0.05). Dose response data are analyzed with a four-parameter logistic curve-fitting program. |
|
References: [1]. Ma L, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013, 3, e109. |
|
LY2784544 is a potent, selective inhibitor of JAK2 with IC50 value of 3 nM.[1]
Janus kinase 2 (JAK2) belongs to the Janus kinase family and is a member of the type II cytokine receptor family. It is a non-receptor tyrosine kinase. The JAK2 mutation (V617F) within the autoinhibitory pseudokinase domain results in a gain-of-function activation of JAK2.The JAK2V617F mutant results in subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5). Then, STAT5 regulates the transcription of genes associated with cell growth, death and differentiation. The JAK2V617F mutant is oncogenic in cells, and sufficient for generating the myeloproliferative neoplasms (MPN) phenotypes in murine models. Mutant JAK2 kinase is an attractive therapeutic target for the therapy of MPNs. To selectively inhibit JAK2V617F but minimizing inhibition of wild-type JAK2 would be an optimal treatment approach.
LY2784544 is a potent and ATP-competitive inhibitor of JAK2 tyrosine kinase. LY2784544 has 8- and 16-fold selectivity for JAK2 than JAK1 and JAK3, respectively. LY2784544 more effective on inhibiting the phosphorylation of STAT5 in Ba/F3-TEL-JAK2 cells than in Ba/F3-TEL- JAK3 and –JAK1 cells with IC 50 of 0.191 (JAK2), 2.904 (JAK1) and 4.744 nM (JAK3). LY2784544 significantly inhibited STAT5 phosphorylation at a concentration range from 50 nM–20 nM in Ba/F3 cells expressing JAK2V617F. On the other hand, LY2784544 showed minimal inhibition of STAT5 phosphorylation at 50 and 200 nM concentrations in IL-3-stimulated Ba/F3 cells which express wild-type JAK2. LY2784544 significantly inhibited the cell proliferation of JAK2V617F-expressing cells with IC50 ＝55 nM. In JAK2V617F-expressing cells, LY2784544 induced apoptosis with EC50±s.d.of 113±0.023 nM measured by Caspase3/7-glo assays.[1]
LY2784544 with a TED50 (threshold effective Dose 50) of 12.7 mg/kg, potently inhibits STAT5 phosphorylation in SCID mice bearing Ba/F3-JAK2V617F-GFP. In mouse hematologic disease model, LY2784544 also dose-dependly reduces Ba/F3-JAK2V617F-GFP tumor burden.[1]
References:
1.Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C et al: Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J 2013, 3:e109.
| Cas No. | 1229236-86-5 | SDF | |
| 别名 | Gandotinib | ||
| 化学名 | 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine | ||
| Canonical SMILES | CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F | ||
| 分子式 | C23H25ClFN7O | 分子量 | 469.94 |
| 溶解度 | ≥ 23.5 mg/mL in DMSO, ≥ 5.65 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1279 mL | 10.6397 mL | 21.2793 mL |
| 5 mM | 0.4256 mL | 2.1279 mL | 4.2559 mL |
| 10 mM | 0.2128 mL | 1.064 mL | 2.1279 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。